Skip to main content

ACAAI 2025 Sanofi | Regeneron | Nov 6, 2025 - Nov 10, 2025

Immunology

Sanofi is committed to advancing the science of immunology through our research and development of innovative therapies for patients with chronic, difficult-to-treat, inflammatory diseases.

Available rooms
1 of 1
  • Asthma

    Asthma is predominately a chronic type 2 inflammatory disease. When uncontrolled, asthma is characterized by impaired lung function, severe exacerbations, recurrent symptoms, and poor quality of life.

  • Chronic Spontaneous Urticaria

    Chronic spontaneous urticaria (CSU) is a systemic, immune-mediated disease characterized by the spontaneous appearance of wheals and/or angioedema leading to debilitating symptoms (e.g., itching and/or burning sensation). Despite a lack of known triggers, CSU can recur for 6 weeks or more resulting in substantial physical, mental, emotional, and socio-economic effects on patients’ quality of life.

  • COPD

  • CRSwNP

    Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease characterized, when uncontrolled, by bilateral nasal polyps, congestion, and impaired sense of smell, that is associated with persistent symptoms and poor quality of life.

  • Eosinophilic Esophagitis

    Eosinophilic Esophagitis (EoE) is a chronic type 2 inflammatory disease characterized by specific histologic changes, dysphagia, and poor quality of life due to esophageal scarring and narrowing.